Vascular Access Device Articles & Analysis
10 news found
Nationally there is a trend moving towards radial artery access versus femoral artery access for endovascular procedures and Q’Apel Medical is leading the way. Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for ...
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, is pleased to announce and welcome Thomas Berryman as Chief Financial Officer. ...
New 35,000 square foot Facility will support the company’s growth and OUS expansion Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today that it will relocate its existing headquarters into a new building at ...
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, is pleased to announce and welcome Jodie Fam as Vice President and General Manager, International. ...
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today it has raised $22 Million in Series C funding. ...
AVA Scientific Meeting 2019 highlights key opportunities for improvement in vascular access from process bundles to emerging new products Introduction Acknowledgment of the importance of the vascular access nurse and team were obvious at this year’s Association for Vascular Access (AVA) ...
The clinical study will evaluate STARgraft as a vascular access graft for dialysis patients and will be conducted in collaboration with University of Washington Medicine. In the United States, more than 470,000 patients with kidney failure rely on thrice-weekly hemodialysis treatment to survive. Maintaining a reliable vascular ...
Healionics’ STARport HD, a novel preclinical stage implantable device that allows needle-free bloodstream access for hemodialysis treatment, has been selected by the American Society of Nephrology (ASN) to be featured at the ASN exhibit booth at Kidney Week 2016 as one of several new technologies portraying the future of kidney disease treatment. Kidney Week 2016 is the 50th annual kidney ...
Healionics Corporation has received a $224,500 Small Business Innovation Research (SBIR) grant award from the National Institute of Diabetes and Digestive and Kidney Diseases division of the National Institutes of Health (NIH) for preclinical studies to develop a novel vascular graft for use with needle-free hemodialysis access ports. Andrew Marshall, PhD, ...
The STAR Biointerface is a textured porous tissue ingrowth layer that enhances the biocompatibility and infection resistance of implanted medical devices. The ingrowth layer can be formed by adhering granules of a porous biomaterial to a device surface. ...